Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibody Specific to the AIMP2-DX2

an antibody and target protein technology, applied in the field of antibodies specific to the target protein, can solve the problems of limited application, no diagnostic data in terms of cell physiology, and high incidence rate and mortality of lung and liver cancers in the world, and achieve the effect of effective treatment of cancer

Inactive Publication Date: 2011-05-19
MEDICINAL BIOCONVERGENCE RES CENT
View PDF12 Cites 62 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention is about a new cancer-specific molecule called AIMP2-DX2, which is specifically expressed in cancer cells and can be used to diagnose cancer more reliably. Antibodies, siRNA, and antisense oligonucleotides specific to AIMP2-DX2 have been found to effectively treat cancer. The invention also includes a recombinant vector carrying a nucleotide sequence encoding AIMP2-DX2, an antisense oligonucleotide, and a pharmaceutical composition for treating cancer. The invention also provides a method for screening for agents that inhibit the formation of a heterodimer between AIMP2-DX2 and AIMP2 proteins, as well as a method for screening for agents that inhibit the expression of the AIMP2-DX2 gene. The invention also includes an isolated siRNA molecule and a recombinant nucleic acid construct that can direct the transcription of siRNA molecules that target AIMP2-DX2. Overall, the invention provides new tools for diagnosing and treating cancer."

Problems solved by technology

However, such methods provide no diagnostic data in terms of cell physiology molecular genetics, while they allow to determine anatomical progress of cancer.
Lung and liver cancers are known to exhibit high incidence rate and mortality over the world.
However, markers for lung and liver cancers so far proposed permit restricted application in the senses that they are also detectable in normal cells.
Therefore, assays or diagnostics using such markers are generally carried out by comparing their expression levels in normal and cancerous cells, resulting in unreliable and erroneous diagnosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody Specific to the AIMP2-DX2
  • Antibody Specific to the AIMP2-DX2
  • Antibody Specific to the AIMP2-DX2

Examples

Experimental program
Comparison scheme
Effect test

examples

Methods

Cell Culture, Chemicals and Cell Cycle Measurement

[0151]Cells were maintained in RPMI-1640 containing 10% FBS. Mouse embryonic fibroblasts (MEFs) were isolated from 12.5-14.5 day embryos and cultivated in DMEM (Dulbecco's Modified Eagle Medium) containing 20% FBS. To evaluate the effect of TGF-13 on cell cycle, cells were incubated with 2 ng / ml TGF-β in serum-free or 1% FBS-containing medium for 24 hr and harvested for FACS analysis. Cell proliferation was also determined by [3H] thymidine incorporation. Cells were incubated in serum-free medium with or without TGF-β for 20 hr, and then in the presence of 1 μCi / ml of [3H] thymidine for 4 hr. The incorporated thymidine was quantified by liquid scintillation counting as previously described (Kim, M. J. et al., Nat. Genet. 34, 330-336(2003)). TGF-β was purchased from R&D system, and anti-Smad2 and anti-Smad4 antibodies from Santa Cruz.

[0152]Normal lung cell line, WI-26, was purchased from Korea Cell Line Bank (KCLB) and NL-20 w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a variant of AIMP2 lacking exon 2 gene, named as AIMP2-DX2 gene, which is specifically expressed in cancer cells. The AIMP2-DX2 gene and siRNA targeting AIMP2-DX2 can be successfully used in the development of diagnosis and treatment of cancer

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation-in-part of U.S. Ser. No. 11 / 264,725, filed Nov. 1, 2005, which claims priority from Korean Patent Application Nos. 10-2004-0097164 and 10-2005-0039073, filed on Nov. 24, 2004 and May 10, 2005, respectively in the Korean Intellectual Property Office. The disclosures of the priority applications, including the sequence listings and tables submitted in electronic form in lieu of paper, are incorporated by reference into the instant specification.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention relates to a variant of AIMP2 lacking exon 2, named as AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2.[0004]2. Description of the Related Art[0005]Cancer is generally diagnosed by radiography examinations such as X-ray radiography, computed tomography and bronchography or bronchoscopy examination. However, such methods provide no diagnostic data in terms of cell physiology molecular ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/566C07K16/40
CPCC07K16/30C12Q1/6886C12Q2600/136G01N2500/04G01N33/57423G01N33/57438C12Q2600/158
Inventor KIM, SUNGHOONCHOI, JIN WOO
Owner MEDICINAL BIOCONVERGENCE RES CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com